Aravive (FRA:VE11) EV-to-EBITDA

: -1.37 (As of Today)

View and export this data going back to 2014. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aravive's enterprise value is €91.41 Mil. Aravive's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was €-66.62 Mil. Therefore, Aravive's EV-to-EBITDA for today is -1.37.

The historical rank and industry rank for Aravive's EV-to-EBITDA or its related term are showing as below:

FRA:VE11' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.26 Med: -0.52 Max: 0.8
Current: -1.4

During the past 11 years, the highest EV-to-EBITDA of Aravive was 0.80. The lowest was -7.26. And the median was -0.52.

FRA:VE11's EV-to-EBITDA is ranked worse than
100% of 550 companies
in the Biotechnology industry
Industry Median: 2.51 vs FRA:VE11: -1.40

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2023-03-22), Aravive's stock price is €1.861. Aravive's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was €-2.089. Therefore, Aravive's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Aravive EV-to-EBITDA Historical Data

The historical data trend for Aravive's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBITDA

0.14

-7.06

-1.77

0.18

-0.42

Aravive Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EV-to-EBITDA																0.18	0.28	0.20	-0.03	-0.42

Competitive Comparison

For the Biotechnology subindustry, Aravive's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Aravive EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Aravive's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aravive's EV-to-EBITDA falls in comparison to its industry or sector. The grey bar indicates the EV-to-EBITDA's extreme value range as defined by GuruFocus.

Aravive EV-to-EBITDA Calculation

Aravive's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	91.409	/	-66.617802000562
	=	-1.37

Aravive's current Enterprise Value is €91.41 Mil.
Aravive's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-66.62 Mil.

Aravive (FRA:VE11) EV-to-EBITDA Explanation

Aravive's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	1.861	/	-2.089
	=	At Loss

Aravive's share price for today is €1.861.
Aravive's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.089.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Aravive EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aravive's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (FRA:VE11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (FRA:VE11) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

ARAV:USA VE11:Germany

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Aravive's lead candidate is batiraxcept, which is is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway.

Aravive (FRA:VE11) Headlines

No Headlines